Medtronic meets US trial endpoint for DES (drug-eluting stent)
This article was originally published in Clinica
Executive Summary
Medtronic has met the goal in a key trial of its Endeavor drug-eluting stent (DES), and expects to gain US market approval for the device later this year, the company has said.